Heyholder
‹ Activism Filings

JEONJINBIO CO., LTD. Q3 operating loss of KRW 0.3 billion, swinging to a loss; revenue KRW 3.4 billion

JEONJINBIO CO., LTD.· Periodic Report

AI summary · Not investment advice

Jeonjin Biopharm sold KRW 3.4 billion worth in Q3 but lost KRW 0.3 billion from its main business, turning from profit to loss versus a year earlier.

Operating profit · 3 months

KRW -328.3 million

Key facts

Revenue (3 months)
KRW 3.4 billion
Net income (3 months)
KRW -321.9 million
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 4.5 billion
Revenue (year to date)
KRW 9.2 billion
Operating profit (prior-year 3 months)
KRW 325.5 million
Operating profit (year to date)
KRW -788.6 million
Net income (prior-year 3 months)
KRW 341.2 million
Net income (year to date)
KRW -711.6 million

Commentary

AI commentary · Not investment advice

What happened

Jeil Bio Pharm's quarterly report covers the 3rd quarter of 2026 on a standalone basis.

In the company's terms

Sales for the 3 months were KRW 3.43 billion, down 23.1% from KRW 4.45 billion in the same period a year earlier. Cumulative sales this year were KRW 9.25 billion.

What changes for shareholders

Operating profit (profit from the core business) for the 3 months was a loss of KRW 328.3 million, a swing from a profit of KRW 325.5 million a year earlier. Cumulative operating profit this year was a loss of KRW 788.6 million.

Net income (final profit after taxes and all costs) for the 3 months was a loss of KRW 321.9 million, versus a profit of KRW 341.2 million a year earlier. Cumulative net income this year was a loss of KRW 711.6 million.

Comments

No comments yet

Comments from shareholders will appear here.